Sefrioui, David http://orcid.org/0000-0002-0821-5642
Beaussire, Ludivine
Gillibert, André
Blanchard, France
Toure, Emmanuel
Bazille, Céline
Perdrix, Anne
Ziegler, Frédéric
Gangloff, Alice
Hassine, Mélanie
Elie, Caroline
Bignon, Anne-Laure
Parzy, Aurélie
Gomez, Philippe
Thill, Caroline
Clatot, Florian
Sabourin, Jean-Christophe
Frebourg, Thierry
Benichou, Jacques
Bouhier-Leporrier, Karine
Gallais, Marie-Pierre
Sarafan-Vasseur, Nasrin
Michel, Pierre
Di Fiore, Frédéric
Article History
Received: 31 July 2020
Revised: 17 April 2021
Accepted: 28 April 2021
First Online: 10 June 2021
Ethics approval and consent to participate
: The study was approved by the institutional review board (Northwest I), and all patients provided written informed consent (NCT01212510). The study was performed in accordance with the Declaration of Helsinki.
: N/A.
: Raw data are available from the corresponding author upon request.
: The authors declare no competing interests.
: This study was supported in part by the Grant “Pierre DURAND & Marie-Thérèse CHEVALIER (2013)” and the pharmaceutical industrial partners Roche, Merck and Amgen France. A grant was also provided by the Charles Nicolle Foundation and the association “des tulipes contre le cancer-Lions Club de France” for financing and acquisition of the digital PCR system used for the detection of circulating tumour DNA. The Northwest Data Center (CTD-CNO) that managed the data was supported by grants from the French National League Against Cancer (LNC) and the French National Cancer Institute (INCa).
Free to read: This content has been made available to all.